Related Experiment Video

Updated: Apr 13, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K

Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis

Evgeny Izumchenko1, David Sidransky2

  • 1Division of Head and Neck Cancer Research, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland.

Cancer Discovery
|May 6, 2015
PubMed

Insights

This study shows that MIG6 acts as a tumor suppressor in lung adenocarcinoma by inhibiting signaling from mutated epidermal growth factor receptor (EGFR). This finding is crucial for understanding EGFR-driven lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Epidermal growth factor receptor (EGFR) signaling is a key driver in many lung adenocarcinomas.
  • Mutations in EGFR are common targets for cancer therapies.
  • The role of MIG6 in regulating EGFR signaling in the context of mutant EGFR-driven lung cancer requires further elucidation.

Purpose of the Study:

  • To investigate the functional role of MIG6 in the context of mutant EGFR signaling.
  • To determine how MIG6 antagonizes or promotes tumor formation in EGFR-mutated lung adenocarcinoma.
  • To elucidate the MIG6-EGFR signaling axis in genetically engineered mouse models.

Main Methods:

  • Utilized genetically engineered mouse models (GEMMs) expressing mutated EGFRs.
  • Developed a MIG6-deficient background in these GEMMs.
  • Analyzed the impact of MIG6 deficiency on tumor formation and EGFR signaling.

Main Results:

  • MIG6 deficiency exacerbates tumor formation in mice with mutated EGFRs.
  • MIG6 antagonizes the oncogenic signaling driven by mutant EGFR.
  • The study provides in vivo evidence for MIG6's tumor-suppressive function.

Conclusions:

  • MIG6 acts as a critical negative regulator of mutant EGFR signaling.
  • MIG6 antagonizes tumor initiation and progression in EGFR-driven lung adenocarcinoma.
  • Understanding the MIG6-EGFR axis offers potential therapeutic strategies for lung cancer.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

957

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K